New use of ACE-I/ARB therapy in AKI survivors without heart failure was not associated with a higher incidence of recurrent hospitalized AKI (adjusted OR 0.71; 95% CI 0.45-1.12).
Cohort (n=10,242)
Does new use of ACE-Is/ARBs increase the risk of recurrent hospitalized AKI in AKI survivors without heart failure?
In AKI survivors without heart failure, initiating ACE-I/ARB therapy does not appear to increase the risk of recurrent hospitalized AKI.
Effect estimate: adjusted OR 0.71 (95% CI 0.45 to 1.12)
Absolute Event Rate: 5.7% vs 6.1%
BACKGROUND AND OBJECTIVES: How to best medically manage patients who survived hospitalized AKI is unclear. Use of renin-angiotensin system blockers in this setting may increase risk of recurrent AKI. DESIGN, SETTING, PARTICIPANTS, 95% CI, 0.45 to 1.12). CONCLUSIONS: In this study of AKI survivors without heart failure, new use of ACE-I/ARB therapy was not independently associated with increased risk of recurrent hospitalized AKI.
Hsu et al. (Mon,) conducted a cohort in Acute Kidney Injury (n=10,242). ACE-Is/ARBs vs. No ACE-Is/ARBs was evaluated on Subsequent episode of hospitalized AKI (adjusted OR 0.71, 95% CI 0.45 to 1.12). New use of ACE-I/ARB therapy in AKI survivors without heart failure was not associated with a higher incidence of recurrent hospitalized AKI (adjusted OR 0.71; 95% CI 0.45-1.12).